BIOR | CEO's experience

Optifinancial Newsletter - Knowledge is power - Brad Mitchell

This is not financial advice nor recommendations. This is purely our own thoughts and opinions regarding the matter discussed below for entertainment purposes. This is not advice and is never intended to be.

Disclosure: We own BIOR securities/shares at the time of publication. This could affect my biases in my analysis.

 

Biora | $0.80


After our Wednesday night twitter call, I was asked about the background of Adi Mohanti who is the CEO of Biora. From the earnings report calls, he seems to be a very confident individual and experienced in this the biotech industry.


Below I detail what his past was and how it could correlate to the transformation of Biora into a top tier biotechnology company.


Directly from Adi’s linkedin, he gives us an insight into what he has done in the past and how he has rounded experience in biotechnology.


 

2000-2002 - He listed his first large job as a General Manager/ Plant manager of Baxter international Inc. (Bioscience)/ Baxalta

He listed that he was the head of business for various sites across the world. He mentions that he was involved with business strategy and planning.


How is Baxalta doing now? What do they do?

Baxalta is a biotech that has 16,000 employees and is primarily involved in therapies over blood haematology, immunology & oncology.


In 2016, Baxalta was taken over by Shire for $32 Billion dollars.

Interestingly, Shire was then bought out by Takeda Pharmaceuticals in 2019 - which we do believe has a contorted interest in Biora’s RSS product line

 

Shire 11 years:

2002-2009 Adi Moved to Shire (which we just talked about buying out Baxalta)

Adi performed VP roles for product GM rare disease & global manufacturing and supply chain. I think this job experience is exactly what we’d want for Biora. He has the knowledge of how product supply chains work and how distribution of products work. This will be helpful in Biora’s productionization of the Technology pills that they are working on. He worked on products for rare/orphan classified diseases (means very rare and high need because no specific products available to treat)


2010-2012 - Adi moved to Switzerland (Stayed with Shre) to oversee and be held responsible over the product development from Pre-clinical all the way to Launch of the products. I believe this is another key experience a CEO needs to have as the head of Biora.


2012-2014 - Now back in San Diego @ Shire, he oversaw a weakened part of the business after some layoffs. He then ended his term there with a successful turnaround and divestiture of that business segment.

 

BioTime

2014-2018 - Became the CEO of BioTime (Stock ticker: LCTX) - His statements here definitely tell me he comes from a mindset of transformation and rebranding - At this point in my thinking, it is easy to see, he has already changed the name of the business from Progenity to Biora. He is most likely strategically working out the partnerships to allow Biora to grow into a late stage and productionized company. I bolded some of his buzz words

 

2015-2020 San Francisco Member of a board:

oversaw development, spin out and take Public from start up. Diagnostics Company with lead assets in liquid biopsy of lung and several other commercial and clinical cancer diagnostic tests”

 

EnCellX

November 2020 - Present: Founded another company called EnCellX - they basically are a company that targets specific T-cells when activated. This could be helpful for a few auto-immune such as Type 1 diabetes, or even Ulcerative Colitis, Chron’s disease which Biora is currently working on.


November 2021 - Present: Biora


Final Thoughts: Seems like we have an experience person running the ship of Biora, I think he is strategic and is also doing his best to execute this year on what might change the future of the company to grow into a large Biotech.

 

Older Thoughts:

Biora Therapeutics is nearing critical mass. We will see extreme upside if they are able to hit upon their goals this year. (FDA approval for phase 1 trial for their DDS), (OBDS meets needs for the 3 concurrent collaborators), RSS could award the company with a large contract from a pharma as well.


Current Price: $0.801 Month Price Forecast: $1.25


2025: $50

The company at this stage will look very different from today. They will have established a dominance in the oral delivery market with a wide moat of research and patent protection. The partnerships that they are working on today will start to bear fruit during this time.

2030: $300-600

If Biora is not bought out, we should see them bloom like Dexcom. They have a medical device that will serve the needs of patients and give doctors the feedback that they will always want to have. It will be hard for doctors who prescribe drugs to not want to use a patient compliance mechanism such as Biora’s DDS or OBDS. Another note to make is that insurance will want to have this data in hand as well. Biora will most likely have many other drug candidates in their pipelines with funding from partners to validate their drugs.


Disclosure: We own BIOR securities/shares at the time of publication

All stocks talked about we have invested in, and do not intend to give advice nor recommend acting upon the information.

 

Thanks for subscribing to the newsletter. If you find this information helps you, please share it with someone else! It will help us out greatly.


Until next week,

Brad Mitchell

and the Optifinancial Team

 

DISCLAIMER

Optifinancial is not a certified financial planner/advisor nor a certified financial analyst nor an economist nor a CPA ;nor an accountant nor a lawyer. Optifinancial is not a finance professional through formal education. Optifinancial believes in and takes pride in a sense of freedom, satisfaction, fulfillment and empowerment of money. The contents on this site/letter/email are for informational and entertainment purposes only and does not constitute financial, accounting, or legal advice. Optifinancial can’t promise that the information shared on our posts is appropriate for you or anyone else. By using our content, you agree to hold Optfinancial or any constituents related to Optifinancial harmless from any ramifications, financial or otherwise, that occur to you as a result of acting on information provided through our site, website, social media and newsletter.


PRIVACY POLICY

Optifinancial does not collect information about you other than (1) what you personally provide if you submit a comment (your email will not be published) or sign up for our newsletter updates and (2) what’s available through normal server logs and Google Analytics. Optifinancial won’t sell or disclose your information to others unless we have received prior written agreement from you (e.g., you agreed to let me share your comment on a post with other readers).


17350 State Highway 249

Ste 220 #3942

Houston, Texas 77064

brad@optifinancialnews.com

436 views0 comments

Recent Posts

See All